ISIS 2105 antiviral data

ISIP announced that a trial of a single dose of the agent as an adjunct to surgical removal of warts didn't achieve statistical significance, as the recurrence rate was much lower than expected from values in the literature. Historical recurrence rates after surgery range from 40-60 percent. In the trial, 15 percent of patients on placebo had wart recurrences.

The antisense oligonucleotide, given as a single dose into the wart at the time of scissors excision, was associated with a 6 percent recurrence rate of warts at the same site vs. 10 percent in the placebo group. ...